Get the Stockscreener App
568.91
6.87%
-41.95
After Hours:
568.30
-0.61
-0.11%
Regeneron Pharmaceuticals Inc stock is traded at $568.91, with a volume of 2.62M.
It is down -6.87% in the last 24 hours and down -10.74% over the past month.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$610.86
Open:
$561.75
24h Volume:
2.62M
Relative Volume:
2.71
Market Cap:
$64.01B
Revenue:
$14.20B
Net Income/Loss:
$4.41B
P/E Ratio:
14.86
EPS:
38.28
Net Cash Flow:
$3.54B
1W Performance:
-2.83%
1M Performance:
-10.74%
6M Performance:
-38.65%
1Y Performance:
-36.26%
1-Day Range:
$542.44
$579.98
1-Week Range:
$542.44
$614.83
52-Week Range:
$525.99
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Earnings call transcript: Regeneron Q1 2025 earnings miss, stock drops 8% - Investing.com
Regeneron Q1 2025 slides: Dupixent drives growth amid EYLEA challenges - Investing.com
Regeneron crumples under the weight of missed Eylea expectations - FirstWord Pharma
Another CRL Prompts Questions About Regeneron’s Regulatory Operations - insights.citeline.com
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Regeneron Crashes 7% On Major Miss For Blockbuster Eye Drug - Investor's Business Daily
Why Regeneron (REGN) Stock Is Moving Today - GuruFocus
Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides - Benzinga
Regeneron Pharmaceuticals Stock Sinks as Eylea Q1 Sales Trail Estimates - Investopedia
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down - Nasdaq
Regeneron (NASDAQ: REGN) Stock Drops: REGN Shares Fall Sharply - paginasiete.bo
Regeneron (REGN) Navigates Q1 Challenges with Strategic Growth P - GuruFocus
Regeneron’s first quarter 2025 results miss expectations - The Pharma Letter
Regeneron (REGN) Price Target Reduced Amid EYLEA Challenges | RE - GuruFocus
Regeneron's first-quarter results miss on lower Eylea demand - Reuters
Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More - MSN
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $925 - marketscreener.com
Spotify, Regeneron lead Tuesday’s market cap stock movers - Investing.com
Regeneron Stock Plummets After Earnings Miss - Barron's
Regeneron (REGN) Faces Setback with Q1 Sales Miss - GuruFocus
Regeneron Faces Setback With Eylea And FDA Rejection - Finimize
Regeneron stock drops as Eylea drives Q1 miss (REGN:NASDAQ) - Seeking Alpha
EC approves Regeneron’s Lynozyfic for advanced multiple myeloma - World Pharmaceutical Frontiers
Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Regeneron Pharma's first-quarter results miss on lower Eylea demand - Yahoo Finance
Regeneron Pharma's First-Quarter Results Miss on Lower Eylea Demand - US News Money
Regeneron Shares Tumble as Eylea Declines Make for a ‘Messy Quarter’ To Come - BioSpace
Regeneron Pharmaceuticals Q1 2025 Earnings: GAAP EPS of $7.27 Mi - GuruFocus
Regeneron Reports First Quarter 2025 Financial and Operating Res - GuruFocus
Regeneron (REGN) Q1 Earnings and Revenue Miss Estimates - GuruFocus
Regeneron (REGN) Q1 Revenue Falls Short of Expectations | REGN S - GuruFocus
Regeneron (REGN) Advances Pipeline and Strengthens Shareholder V - GuruFocus
Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma - PMLiVE
Regeneron: Q1 Earnings Snapshot - CTPost
REGENERON PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Regeneron Pharmaceuticals Reports Q1 2025 Financial Results - TradingView
Regeneron Pharmaceuticals' Q1 Adjusted Earnings, Revenue Fall - marketscreener.com
Regeneron (NASDAQ:REGN) Misses Q1 Sales Targets - Yahoo Finance
Regeneron Unveils Massive $7B Growth Plan as Dupixent Sales Surge 19%, EYLEA HD Gains Momentum - Stock Titan
Nebula Research & Development LLC Sells 1,957 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma - Yahoo Finance
Familial Lipoprotein Lipase Deficiency Market Trends, Size, - openPR.com
Price T Rowe Associates Inc. MD Purchases 810,144 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Highlights New Real-World And Clinical Data On EYLEA HD At ARVO 2025 - Nasdaq
Aspergillosis Market Expected to Rise by 2034, Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, - Barchart.com
Regeneron Pharmaceuticals (NasdaqGS:REGN) Gains Conditional EC Approval For Lynozyfic In Multiple Myeloma - Yahoo Finance
NewEdge Advisors LLC Sells 1,630 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts? - Yahoo Finance
Regeneron wins EC approval for Lynozyfic in MM - The Pharma Letter
Regeneron expands US manufacturing with $3B Fujifilm partnership - Manufacturing Dive
Regeneron scores EU nod for bispecific antibody Lynozyfic, setting up clash with J&J and Pfizer - Fierce Pharma
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):